Purchase Order HT941025P0011
Award Date
1/14/25
Potential Completion Date
9/30/27
Potential Value
$194K
Federal Agency
Defense Health Agency
Awardee
Cerus Corporation
Ultimate Awardee
Not listed
NAICS Category
325413 - In-Vitro Diagnostic Substance Manufacturing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Agana Heights, Guam
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This firm fixed-price purchase order contract was awarded by the Defense Health Agency (DHA) to Cerus Corporation, a biomedical products company specializing in blood safety technologies and pathogen reduction systems. The $369,384 contract is for the provision of Cerus' proprietary INTERCEPT Blood System, which uses riboflavin and ultraviolet light to inactivate pathogens in blood components, including platelets and plasma. This pathogen reduction technology plays a critical role in reducing...
This is a firm fixed-price purchase order awarded by the Defense Health Agency (DHA) to Cerus Corporation, a biomedical products company specializing in blood safety technologies. The contract is for the service and maintenance of the Cerus INTERCEPT Illuminator, which is a key component of the company's proprietary INTERCEPT Blood System. The INTERCEPT system uses riboflavin and ultraviolet light to inactivate pathogens in blood components, including platelets, plasma, and red blood cells,...
This is a firm fixed-price purchase order contract awarded by the Defense Health Agency to Cerus Corporation, a biomedical products company specializing in blood safety technologies. The contract, valued at $146,200.00, is for the procurement of INTERCEPT Blood System processing sets for dual storage. The INTERCEPT system uses riboflavin and ultraviolet light to inactivate pathogens in blood components such as platelets and plasma, enhancing blood safety.
Cerus has a history of supplying its...
The Defense Health Agency awarded a Firm Fixed Price, $186,048.00 purchase order contract to Cerus Corporation, a biomedical products manufacturer, for the drop shipment of medical supplies. The contract is sole source and not set aside. The supplies include the INTERCEPT Blood System technology, which uses riboflavin and UV light to inactivate pathogens in blood platelets and plasma. Cerus has received over 20 federal contract awards since 2002 from agencies such as the Department of...
This federal contract award, valued at $127,680.00, was issued by the Defense Health Agency to Cerus Corporation, a biomedical products company specializing in blood safety technologies. The contract is for the provision of INTERCEPT Platelet Processing Sets, which use Cerus' proprietary INTERCEPT Blood System to inactivate pathogens in blood components. The INTERCEPT system employs riboflavin and ultraviolet light to reduce the risk of transfusion-transmitted infections. This contract does...
This federal contract award is for the supply of INTERCEPT Platelet Small Volume Sets by Cerus Corporation, a biomedical products company specializing in blood safety technologies and pathogen reduction systems. The contract, valued at $104,256.00, was awarded by the Defense Health Agency, a defense agency within the Department of Defense. The contract is a Firm Fixed Price Purchase Order with a period of performance through September 3, 2024. Cerus Corporation has a history of providing its...
This federal contract award to Cerus Corporation, a biomedical products company, is for the delivery of INTERCEPT Platelet Processing Kits. The award, valued at $232,128.00, was made by the Defense Health Agency (DHA), a component of the Department of Defense. The contract has a period of performance ending on September 30, 2027. Cerus Corporation's INTERCEPT Blood System, which uses riboflavin and ultraviolet light to inactivate pathogens in blood components, plays a crucial role in reducing...
This federal contract award was issued by the Bureau of Medicine and Surgery, a defense agency, to Cerus Corporation, a biomedical products company specializing in blood safety technologies. The $138,800 firm-fixed-price contract is for the supply of INTERCEPT Illuminator 60 Hz equipment and INTERCEPT Platelet Processing Sets with Dual Storage, as well as related services, to support the agency's blood product safety requirements. Cerus Corporation's proprietary INTERCEPT Blood System uses...
The National Institutes of Health (NIH) awarded a $28,924.80 firm fixed price purchase order contract to Cerus Corporation for the delivery of INTERCEPT Platelet Processing Sets with Dual Storage Containers. This sole-source contract is for the Department of Transfusion Medicine and will run from April 1, 2025 to September 30, 2025. Cerus Corporation's proprietary INTERCEPT technology is used to reduce the potential for virus replication in platelets, ensuring the safety of transfused blood...
This is a firm fixed-price purchase order awarded by the Defense Health Agency to Cerus Corporation, a for-profit manufacturer of biomedical products. The $21,955.08 contract is for the maintenance and services of the Cerus INTERCEPT Blood System located at William Beaumont Army Medical Center in Fort Bliss, Texas.
The contract has a base period of one year starting on May 1, 2024 and includes two one-year option periods, bringing the potential completion date to April 30, 2027. There was no...